NuPathe Announces Allowance of U.S. Patent Application for NP201

NuPathe Announces Allowance of U.S. Patent Application for NP201 
CONSHOHOCKEN, PA -- (Marketwired) -- 04/25/13 --  NuPathe Inc.
(NASDAQ: PATH) today announced that the United States Patent and
Trademark Office (USPTO) has issued a notice of allowance for U.S.
Patent application 12/074,101 entitled "Implants for the Treatment of
Dopamine Associated States." This application relates to a
biodegradable polymer implant capable of delivering a dopamine
modulating compound, such as ropinirole, with little or no initial
burst and maintaining an effective plasma level for a specified
period of time. Given this action, NuPathe expects the patent to
issue within the next few months. Once issued, it will provide patent
protection into July 2028 for NP201, NuPathe's long-term
biodegradable ropinirole implant for the treatment of Parkinson's
disease. NuPathe has additional licensed patent applications pending
in the U.S. and other territories for NP201. 
"We are pleased with the USPTO's allowance and believe a strong
patent portfolio for NP201 is an important valuable component of the
value proposition as we seek development partners for this program,"
said Armando Anido, chief executive officer of NuPathe. "While
obtaining this patent is important, we remain focused on securing
commercial partners and preparing for the launch of ZECUITY."  
About NP201
 NP201 is a long-acting formulation of ropinirole, a
generic, FDA-approved dopamine agonist. Using NuPathe's long-acting
delivery (LAD) technology, NP201 is designed to provide continuous
delivery of Parkinson's disease medication for up to two months in an
easy-to-administer and tolerable dose formulation. NuPathe is seeking
a development partner for this product candidate. 
About NuPathe
 NuPathe Inc. is a specialty pharmaceutical company
focused on innovative neuroscience solutions for diseases of the
central nervous system including neurological and psychiatric
disorders. NuPathe's lead product, Zecuity(TM) (sumatriptan
iontophoretic transdermal system), has been approved by the FDA for
the acute treatment of migraine with or without aura in adults. In
addition to Zecuity, NuPathe has two proprietary product candidates
based on its LAD(TM), or Long-Acting Delivery, biodegradable implant
technology that allows delivery of therapeutic levels of medication
over a period of months with a single dose. NP201, for the continuous
symptomatic treatment of Parkinson's disease, utilizes a leading
FDA-approved dopamine agonist, ropinirole, and is being developed to
provide up to two months of continuous delivery. NP202, for the
long-term treatment of schizophrenia and bipolar disorder, is being
developed to address the long-standing problem of patient
noncompliance by providing three months of continuous delivery of
risperidone, an atypical antipsychotic. NuPathe is actively seeking
partnerships to maximize the commercial potential for Zecuity and its
other product candidates in the U.S. and territories throughout the
world. 
For more information about NuPathe, please visit our website at
www.nupathe.com. You can also follow us on StockTwits
(stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare
(slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com). 
Cautionary Note Regarding Forward-Looking Statements
 This press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements
that are not historical facts are hereby identified as
forward-looking statements for this purpose and include, among
others, statements relating to: the issuance of a patent for U.S.
patent application 12/074,101; the scope and duration of patent
protection afforded by the referenced patent and the Company's other
intellectual property; the potential benefits of, and commercial
opportunity for, NuPathe's product candidates; and other statements
relating to NuPathe's plans, objectives, expectations and beliefs
regarding its future operations, performance, financial condition and
other future events. 
Forward-looking statements are based upon management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and other factors that could cause actual results and
events to differ materially from those indicated herein including,
among others: risks and uncertainties relating to intellectual
property; NuPathe's ability to obtain commercial partners for Zecuity
and its product candidates; NuPathe's ability to obtain additional
capital to launch Zecuity and continue as a going concern; and the
risks, uncertainties and other factors discussed in NuPathe's Annual
Report on Form 10-K for the year ended December 31, 2012 under the
caption "Risk Factors" and elsewhere in such reports, which are
available on NuPathe's website at www.nupathe.com in the "Investor
Relations -- SEC Filings" section. While NuPathe may update certain
forward-looking statements from time to time, it specifically
disclaims any obligation to do so, whether as a result of new
information, future developments or otherwise. You are cautioned not
to place undue reliance on any forward-looking statements. 
Contact Information:  
INVESTOR CONTACTS:
Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com 
Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130 
MEDIA CONTACT:
Sage Strategic Marketing
Jennifer Guinan
(610) 410-8111
jennifer@sagestrat.com 
 
 
Press spacebar to pause and continue. Press esc to stop.